苯达莫司汀联合利妥昔单抗、依托泊苷和卡铂(T(R)EC)治疗复发或难治性侵袭性淋巴瘤:一项前瞻性多中心1/2期临床试验
这项多中心1/2期研究在复发或难治性弥漫大B细胞淋巴瘤(DLBCL)和经典霍奇金淋巴瘤(HL)患者中,用苯达莫司汀替代(R)ICE方案中的异环磷酰胺组成T(R)EC方案。48例患者中71%为难治性疾病,未观察到剂量限制性毒性,苯达莫司汀推荐2期剂量为120 mg/m2每日,第1、2天给药。HL缓解率85%(完全缓解70%),DLBCL缓解率65%(完全缓解40%),32例中30例干细胞采集成功。
要点
- T(R)EC方案未观察到剂量限制性毒性,苯达莫司汀推荐2期剂量为120 mg/m2每日,第1、2天给药。
- HL缓解率85%(完全缓解70%),DLBCL缓解率65%(完全缓解40%)。
- 32例中30例干细胞采集成功,最常见≥3级非血液学毒性为发热性中性粒细胞减少(8%)和脱水(8%)。
核心结论
- T(R)EC方案安全性好,可获得高缓解率,成功动员外周血干细胞,与RICE相比具有优势,为复发或难治性DLBCL和HL提供有效的门诊治疗选择。
研究设计与样本
- 多中心1/2期临床研究,纳入复发或难治性弥漫大B细胞淋巴瘤(DLBCL)和经典霍奇金淋巴瘤(HL)患者48例,其中71%为难治性疾病。
主要发现
- 未观察到剂量限制性毒性。
- HL缓解率为85%(完全缓解70%),DLBCL缓解率为65%(完全缓解40%)。
- 32例患者中30例干细胞采集成功。
- 最常见≥3级非血液学毒性为发热性中性粒细胞减少(8%)和脱水(8%)。
关键数值与推荐
- 苯达莫司汀推荐2期剂量为120 mg/m2每日,第1、2天给药,联合卡铂、依托泊苷和利妥昔单抗(仅用于CD20+淋巴瘤),最多2个周期。
临床怎么用
- T(R)EC方案可作为复发或难治性DLBCL和HL患者的有效门诊治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We sought to develop a safe and effective outpatient salvage regimen by replacing ifosfamide within the (R)ICE (rituximab, ifosfomide, carboplatin, etoposide) regimen with bendamustine (T(R)EC) via a multicentre phase I/II study for patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) and classic Hodgkin lymphoma (HL). Therapy consisted of 60-120 mg/m2 per day bendamustine on days 1 and 2 in combination with carboplatin, etoposide and rituximab (only for CD20+ lymphoma) used in the (R)ICE regimen for up to 2 cycles. The objectives were to define a maximally tolerated dose (MTD) of bendamustine, determine safety and toxicity, assess efficacy, and evaluate impact on stem cell collection. Forty-eight patients were treated of which 71% had refractory disease. No dose-limiting toxicities were observed. The recommended phase II dose of bendamustine was 120 mg/m2 per day on days 1 and 2. Response rates were 85% (70% complete response, CR) in HL, and 65% (40% CR) in DLBCL. Stem cell collection was successful in 30 of 32 patients. The most common non-haematological toxicities ≥grade 3 were febrile neutropenia (8%) and dehydration (8%). The T(R)EC regimen safely yields high response rates, successfully mobilizes peripheral blood stem cells and compares favourably to RICE, offering an effective outpatient treatment option for patients with relapsed or refractory DLBCL and HL.
引用
- Budde LE, Wu D, Martin DB, et al. Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial. Br J Haematol. 2018. PMID: 30596402. doi:10.1111/bjh.15585
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。